What is the 13F Pro Quality Score for SRTS?

13F Pro ranks Sensus Healthcare, Inc. (SRTS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SRTS's current score at https://13fpro.ai/research/SRTS (free sign-up required for the full ranking).

Where does 13F Pro source SRTS data?

All Sensus Healthcare, Inc. fundamentals and ownership data come directly from SEC EDGAR. Sensus Healthcare, Inc. files with the SEC under CIK 1494891. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SRTS in?

Sensus Healthcare, Inc. (SRTS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SRTS research updated on 13F Pro?

SRTS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sensus Healthcare, Inc.(SRTS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1494891 SRTS stock profile & AI dashboard →

13F Pro Quality Score

18.0/100

Rank #2,710 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

9.1/100

Profitability

15.9/100

Balance Sheet

14.7/100

Earnings Quality

30.0/100

Free Cash Flow

26.4/100

Institutional Flow

27.9/100

Revenue Scale

7.9/100

Dilution Risk

55.2/100

SRTS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sensus Healthcare, Inc. (SRTS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRTS at 18.0/100 on a 32-signal composite quality model, placing it at rank #2,710 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (7.9) and revenue growth (9.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Sensus Healthcare, Inc. reports quarterly revenue of $3.4M, net income of $-2.6M, free cash flow of $-3.8M. Top institutional holders of SRTS by reported 13-F value include Pacific Ridge Capital Partners,, VANGUARD CAPITAL MANAGEMENT, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. SRTS trades on the Nasdaq exchange and files with the SEC under CIK 1494891. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sensus Healthcare, Inc. directly from SEC EDGAR. Sensus Healthcare, Inc.'s 13F Pro composite quality score has ranged between 16 and 74 since 2022, currently 18.0 — a stable long-term trajectory across 20 quarterly and live scoring snapshots.

✦

Fun facts about Sensus Healthcare, Inc.

Quirks, history, and lore behind SRTS — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. medical device company · listed on Nasdaq · headquartered in Florida.
2
The Numbers
Annual revenue in the tens of millions — this is a niche player, not a giant — with a focus on keeping costs low and targeting a highly specific treatment market.
3
The History
Founded in the 2010s, it went public relatively quickly and built its business around a single core technology platform rather than a broad product portfolio.
4
The Secret
Its devices use superficial radiation therapy (SRT) — a non-surgical, non-invasive approach — to treat conditions that most people assume require a scalpel or chemo.
5
The Lore
Its flagship technology targets non-melanoma skin cancers and keloid scars, positioning dermatologists as the heroes who zap problems without ever cutting a patient open.
6
The Giveaway
The ticker is SRTS, the name rhymes with "senses," and it makes the SRT-100 — a machine that quietly nukes skin lesions in a doctor's office in Boca Raton.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.4M

Net Income

Q1 2026

$-2.6M

Free Cash Flow

Q1 2026

$-3.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-34.3% YoY

$27.5MFY 2025

FY19 $27.3MFY22 $44.5MFY24 $41.8MFY25 $27.5M

Net Income

-216.1% YoY

$-7.7MFY 2025

FY19 $-1.7MFY22 $24.2MFY24 $6.6MFY25 $-7.7M

Operating Income

-227.4% YoY

$-10.3MFY 2025

FY19 $-2.0MFY22 $14.8MFY24 $8.1MFY25 $-10.3M

EPS (Diluted)

-214.6% YoY

$-0.47FY 2025

FY19 —FY22 $1.46FY24 $0.41FY25 $-0.47

Total Assets

-14.7% YoY

$53.0MFY 2025

FY19 $36.9MFY22 $56.7MFY24 $62.2MFY25 $53.0M

Op. Cash Flow

+163.5% YoY

$528.0KFY 2025

FY19 $-2.1MFY22 $-1.4MFY24 $-831.0KFY25 $528.0K

Metric	FY 2025	FY 2024	FY 2022	FY 2019	FY 2018	FY 2016
Revenue	$27.5M -34.3%	$41.8M -6.1%	$44.5M +63.3%	$27.3M +3.2%	$26.4M +78.4%	$14.8M
Net Income	$-7.7M -216.1%	$6.6M -72.6%	$24.2M +1526.1%	$-1.7M +16.0%	$-2.0M -483.9%	$-346.4K
Operating Income	$-10.3M -227.4%	$8.1M -45.5%	$14.8M +853.5%	$-2.0M +1.8%	$-2.0M -452.3%	$-363.1K
EPS (Diluted)	$-0.47 -214.6%	$0.41 -71.9%	$1.46	—	—	—
Total Assets	$53.0M -14.7%	$62.2M +9.6%	$56.7M +53.7%	$36.9M +11.0%	$33.3M +75.5%	$18.9M
Operating Cash Flow	$528.0K +163.5%	$-831.0K +41.1%	$-1.4M +33.0%	$-2.1M	—	—

AI Insight: SRTS Financial Trends

Sensus Healthcare is in free fall: revenue collapsed 67% from Q2 2024 to Q1 2026, with operating losses now structural and cash burn accelerating.

• Revenue plummeted from $9M (Q2 2024) to $3M (Q1 2026), a 67% decline over 8 quarters with no stabilization signs.

• Operating income swung from +$2M (Q2 2024) to -$4M (Q1 2026); company now unprofitable for 5 consecutive quarters.

• Operating cash flow deteriorated to -$4M in Q1 2026 from +$4M in Q2 2024, signaling severe operational stress.

• Equity eroded from $56M (Q4 2024 peak) to $46M (Q1 2026), a 18% decline reflecting cumulative losses.

⚠ Quarterly cash burn now -$4M; at current run rate, equity runway is approximately 11–12 quarters without revenue recovery.

⚠ Q1 2026 revenue of $3M represents lowest quarter on record; no revenue inflection visible in 8-quarter series.

AI Insight: SRTS Ratio Trends

Sensus Healthcare has collapsed into deep unprofitability, with operating margin plummeting to -128.4% in Q1 2026 from +21.4% in Q2 2024.

• Operating margin deteriorated sharply from +21.4% (Q2 2024) to -128.4% (Q1 2026), a 150pp swing signaling severe operational distress.

• Net profit margin collapsed to -77.4% in Q1 2026 versus +17.4% in Q2 2024, indicating near-total loss of profitability.

• ROIC turned deeply negative at -38.3% (Q1 2026), down from +15.0% in Q2 2024, destroying shareholder value at an accelerating pace.

⚠ Q4 2025 marked the inflection into severe losses; Q1 2026 deteriorated further, suggesting ongoing structural issues, not temporary headwinds.

⚠ TTM metrics are worse than latest quarter, indicating sustained multi-quarter losses with no stabilization yet visible.

Get alerted when SRTS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sensus Healthcare, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SRTS

Pacific Ridge Capital Partners, LLC
$3.2M796,072 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.6M648,225 sh
DIMENSIONAL FUND ADVISORS LP
$1.5M387,392 sh
Divisadero Street Capital Management, LP
$1.1M286,078 sh
RENAISSANCE TECHNOLOGIES LLC
$1.0M252,234 sh
UBS Group AG
$688.0K172,870 sh
GEODE CAPITAL MANAGEMENT, LLC
$659.0K165,550 sh
Meros Investment Management, LP
$606.6K152,418 sh
Sachetta, LLC
$599.0K150,508 sh
Greenline Wealth Management LLC
$512.5K128,774 sh

Fund	Value	Shares
Pacific Ridge Capital Partners, LLC	$3.2M	796,072
VANGUARD CAPITAL MANAGEMENT LLC	$2.6M	648,225
DIMENSIONAL FUND ADVISORS LP	$1.5M	387,392
Divisadero Street Capital Management, LP	$1.1M	286,078
RENAISSANCE TECHNOLOGIES LLC	$1.0M	252,234
UBS Group AG	$688.0K	172,870
GEODE CAPITAL MANAGEMENT, LLC	$659.0K	165,550
Meros Investment Management, LP	$606.6K	152,418
Sachetta, LLC	$599.0K	150,508
Greenline Wealth Management LLC	$512.5K	128,774

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SRTS on your watchlist

Track score changes the day Sensus Healthcare, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SRTS a good stock to buy?

13F Pro's AI-powered analysis of Sensus Healthcare, Inc. (SRTS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SRTS are available on the SRTS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SRTS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SRTS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sensus Healthcare, Inc.'s investment landscape.